Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia 11Lymphoma 10Breast Neoplasms 10Lymphoma, Large B-Cell, Diffuse 7Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 5Multiple Myeloma 4Graft vs Host Disease 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Anemia, Refractory, with Excess of Blasts 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Congenital Abnormalities 2Burkitt Lymphoma 2Anemia, Refractory 2Virus Diseases 1Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 1Epirubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × HER2-negative Breast Cancer × Cyclophosphamide × Clear all
NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting
260 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡